PORT WASHINGTON, NY – September 26, 2017: Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the following new additions to the Allegro™ single-use chromatography and Cadence™ continuous bioprocessing product portfolios. Each product enables scalable process integration and intensification for biopharmaceutical manufacturers, while drastically reducing resource use, process time, user risk and overall facility footprint. The technologies will be showcased this week in booths #219 and #319 at the BPI 2017 event in Boston, MA.

Allegro Single-Use Chromatography System: The latest addition to the industry’s first complete, automated platform of scalable single-use solutions — R&D to process scale — will be previewed during the BPI event. The flexible single-use chromatography system design enables installation of two different sized manifolds, with a flow range of 10 to 900 L/h. In addition, the system can accommodate applications utilizing membrane chromatography. 

Cadence BioSMB Process 80 System: This modular 80 liter/hour process scale continuous multicolumn chromatography system has been built specifically to support small-scale process development, with perfusion bioreactor-based compatibility.

Cadence BioSMB Process 350 System: This modular 350 liter/hour process scale continuous multicolumn chromatography system allows for scalable process flexibility, while still delivering the advantages of minimized facility footprint and resource consumption. It has been designed for fed-batch applications of up to 2000 L.

Cadence Virus Inactivation System: Designed to complement the Cadence BioSMB Process 80 and 350 systems, this fully-automated low-pH virus inactivation system can be integrated into batch, semi- or fully continuous processes.

“A changing market has increased demand for drug manufacturers to innovate, thereby driving the need for critical automated end-to-end traditional and single-use process solutions. This is especially true as many manufacturers look to pursue the advantages of semi- or fully-continuous bioprocessing approaches,” explained Martin Smith, Pall Chief Technology Officer. “The latest additions to our technology portfolio provide the support manufacturers need, and carry forward Pall’s promise to bring continuous bioprocesses to life. We are happy to introduce these new technologies to the industry during BPI 2017 this week.”

The Pall Life Sciences team is onsite at BPI 2017 through September 28 in booths #219 and #319. To request a meeting during the event, please email biopharm@pall.com. To learn more about how Pall Life Sciences supports the biopharmaceutical industry, please visit www.pall.com/biopharm.

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.


Or follow us on social media: YouTube - LinkedIn - Twitter

Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.